Aptose Biosciences Inc. (APS.TO)
CAD 0.27
(0.0%)
CAD 0.27
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.01 Million USD | -22.1% |
| 2022 | 1.3 Million USD | 127.0% |
| 2021 | 574 Thousand USD | -46.55% |
| 2020 | 1.07 Million USD | -29.9% |
| 2019 | 1.53 Million USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | -100.0% |
| 2014 | 840.27 Thousand USD | 72.68% |
| 2013 | 486.6 Thousand USD | 0.0% |
| 2012 | - USD | -100.0% |
| 2011 | 873.37 Thousand USD | 0.0% |
| 2010 | - USD | -100.0% |
| 2009 | 947.75 Thousand USD | -92.85% |
| 2008 | 13.25 Million USD | 3.44% |
| 2007 | 12.81 Million USD | 14.81% |
| 2006 | 11.16 Million USD | 11.7% |
| 2005 | 9.99 Million USD | 22.79% |
| 2004 | 8.13 Million USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 919 Thousand USD | -9.46% |
| 2024 Q2 | 818 Thousand USD | -10.99% |
| 2023 Q3 | 1.11 Million USD | -7.81% |
| 2023 Q1 | 1.22 Million USD | -6.06% |
| 2023 Q2 | 1.2 Million USD | -1.63% |
| 2023 Q4 | 1.01 Million USD | -8.56% |
| 2023 FY | 1.01 Million USD | -22.1% |
| 2022 Q2 | 401 Thousand USD | -24.2% |
| 2022 Q1 | 529 Thousand USD | -7.84% |
| 2022 Q3 | 271 Thousand USD | -32.42% |
| 2022 Q4 | 1.3 Million USD | 380.81% |
| 2022 FY | 1.3 Million USD | 127.0% |
| 2021 Q2 | 829 Thousand USD | -12.74% |
| 2021 Q3 | 700 Thousand USD | -15.56% |
| 2021 Q4 | 574 Thousand USD | -18.0% |
| 2021 FY | 574 Thousand USD | -46.55% |
| 2021 Q1 | 950 Thousand USD | -11.55% |
| 2020 Q4 | 1.07 Million USD | -10.13% |
| 2020 Q3 | 1.19 Million USD | -8.36% |
| 2020 Q2 | 1.3 Million USD | -8.1% |
| 2020 Q1 | 1.41 Million USD | -7.38% |
| 2020 FY | 1.07 Million USD | -29.9% |
| 2019 Q3 | 1.63 Million USD | -4.16% |
| 2019 Q1 | 1.8 Million USD | 0.0% |
| 2019 Q4 | 1.53 Million USD | -6.41% |
| 2019 FY | 1.53 Million USD | 0.0% |
| 2019 Q2 | 1.7 Million USD | -5.48% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 FY | - USD | -100.0% |
| 2015 Q1 | 218.48 Thousand USD | 25901.84% |
| 2015 Q2 | 229.59 Thousand USD | 5.08% |
| 2015 Q3 | - USD | -100.0% |
| 2014 Q2 | 486.6 Thousand USD | -65.11% |
| 2014 Q4 | 840.28 USD | -99.83% |
| 2014 Q1 | 1.39 Million USD | -2.32% |
| 2014 FY | 840.27 Thousand USD | 72.68% |
| 2014 Q3 | 488.27 Thousand USD | 0.34% |
| 2013 Q3 | 795.86 Thousand USD | 0.0% |
| 2013 Q4 | 1.42 Million USD | 79.42% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 FY | 486.6 Thousand USD | 0.0% |
| 2012 Q3 | - USD | -100.0% |
| 2012 Q1 | 301.74 Thousand USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 FY | - USD | -100.0% |
| 2012 Q2 | 873.37 Thousand USD | 189.45% |
| 2011 Q3 | - USD | 0.0% |
| 2011 FY | 873.37 Thousand USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 Q2 | 947.75 Thousand USD | 0.0% |
| 2010 Q4 | - USD | -100.0% |
| 2010 Q3 | 1.41 Million USD | 49.25% |
| 2010 FY | - USD | -100.0% |
| 2009 Q2 | 13.25 Million USD | 20.93% |
| 2009 Q3 | - USD | -100.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 FY | 947.75 Thousand USD | -92.85% |
| 2009 Q1 | 10.96 Million USD | 0.75% |
| 2008 Q3 | 12.34 Million USD | -3.63% |
| 2008 FY | 13.25 Million USD | 3.44% |
| 2008 Q4 | 10.87 Million USD | -11.91% |
| 2008 Q1 | 12.74 Million USD | 4.78% |
| 2008 Q2 | 12.81 Million USD | 0.55% |
| 2007 FY | 12.81 Million USD | 14.81% |
| 2007 Q1 | 9.98 Million USD | -0.46% |
| 2007 Q3 | 11.23 Million USD | 0.62% |
| 2007 Q4 | 12.16 Million USD | 8.31% |
| 2007 Q2 | 11.16 Million USD | 11.81% |
| 2006 Q4 | 10.02 Million USD | -1.2% |
| 2006 Q3 | 10.15 Million USD | 1.59% |
| 2006 Q2 | 9.99 Million USD | 5.47% |
| 2006 FY | 11.16 Million USD | 11.7% |
| 2006 Q1 | 9.47 Million USD | 4.61% |
| 2005 Q4 | 9.05 Million USD | 3.46% |
| 2005 Q3 | 8.75 Million USD | 7.57% |
| 2005 Q2 | 8.13 Million USD | 51.49% |
| 2005 Q1 | 5.37 Million USD | 103.93% |
| 2005 FY | 9.99 Million USD | 22.79% |
| 2004 FY | 8.13 Million USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q4 | 2.63 Million USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1998 Q4 | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Appili Therapeutics Inc. | 8.18 Million CAD | 87.599% |
| Eupraxia Pharmaceuticals Inc. | 13.78 Million CAD | 92.635% |
| Helix BioPharma Corp. | - CAD | -Infinity% |
| Microbix Biosystems Inc. | 6.64 Million CAD | 84.726% |
| Medicenna Therapeutics Corp. | - CAD | -Infinity% |
| Satellos Bioscience Inc. | - CAD | -Infinity% |
| Oncolytics Biotech Inc. | 423 Thousand CAD | -139.953% |
| Sernova Corp. | 136.12 Thousand CAD | -645.649% |